KR20190086681A - 면역 반응을 향상시키기 위한 메신저 리보핵산 및 그의 사용 방법 - Google Patents
면역 반응을 향상시키기 위한 메신저 리보핵산 및 그의 사용 방법 Download PDFInfo
- Publication number
- KR20190086681A KR20190086681A KR1020197014935A KR20197014935A KR20190086681A KR 20190086681 A KR20190086681 A KR 20190086681A KR 1020197014935 A KR1020197014935 A KR 1020197014935A KR 20197014935 A KR20197014935 A KR 20197014935A KR 20190086681 A KR20190086681 A KR 20190086681A
- Authority
- KR
- South Korea
- Prior art keywords
- antigen
- polypeptide
- composition
- mrna
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000028993 immune response Effects 0.000 title claims abstract description 169
- 238000000034 method Methods 0.000 title claims abstract description 79
- 229920002477 rna polymer Polymers 0.000 title description 4
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 441
- 239000000427 antigen Substances 0.000 claims abstract description 379
- 108091007433 antigens Proteins 0.000 claims abstract description 378
- 102000036639 antigens Human genes 0.000 claims abstract description 378
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 309
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 255
- 229920001184 polypeptide Polymers 0.000 claims abstract description 252
- 230000011664 signaling Effects 0.000 claims abstract description 56
- 102000002227 Interferon Type I Human genes 0.000 claims abstract description 44
- 108010014726 Interferon Type I Proteins 0.000 claims abstract description 44
- 230000037361 pathway Effects 0.000 claims abstract description 28
- 230000003308 immunostimulating effect Effects 0.000 claims description 196
- 239000003022 immunostimulating agent Substances 0.000 claims description 164
- 229960001438 immunostimulant agent Drugs 0.000 claims description 160
- 239000000203 mixture Substances 0.000 claims description 153
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 134
- 150000002632 lipids Chemical class 0.000 claims description 125
- 239000002105 nanoparticle Substances 0.000 claims description 125
- 206010028980 Neoplasm Diseases 0.000 claims description 87
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 75
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 claims description 74
- 108010050904 Interferons Proteins 0.000 claims description 72
- 230000035772 mutation Effects 0.000 claims description 71
- 102000014150 Interferons Human genes 0.000 claims description 69
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 claims description 68
- 101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 claims description 67
- 102000050022 human STING1 Human genes 0.000 claims description 66
- 230000004936 stimulating effect Effects 0.000 claims description 63
- 229940079322 interferon Drugs 0.000 claims description 62
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 claims description 61
- 201000011510 cancer Diseases 0.000 claims description 51
- 239000008194 pharmaceutical composition Substances 0.000 claims description 51
- 230000004044 response Effects 0.000 claims description 50
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 claims description 48
- 239000003937 drug carrier Substances 0.000 claims description 48
- 230000001404 mediated effect Effects 0.000 claims description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 239000003112 inhibitor Substances 0.000 claims description 44
- 230000005867 T cell response Effects 0.000 claims description 41
- -1 IKK Proteins 0.000 claims description 40
- 230000000694 effects Effects 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 239000002773 nucleotide Substances 0.000 claims description 36
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 claims description 35
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 claims description 34
- 230000016396 cytokine production Effects 0.000 claims description 33
- 230000007112 pro inflammatory response Effects 0.000 claims description 33
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims description 32
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims description 32
- 230000001976 improved effect Effects 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 230000027455 binding Effects 0.000 claims description 27
- 101000595554 Homo sapiens TIR domain-containing adapter molecule 2 Proteins 0.000 claims description 26
- 101000649115 Homo sapiens Translocating chain-associated membrane protein 1 Proteins 0.000 claims description 26
- 102100027965 Translocating chain-associated membrane protein 1 Human genes 0.000 claims description 26
- 230000015572 biosynthetic process Effects 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 24
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims description 23
- 230000001717 pathogenic effect Effects 0.000 claims description 23
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 22
- 102100033467 L-selectin Human genes 0.000 claims description 22
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims description 22
- 102000002689 Toll-like receptor Human genes 0.000 claims description 22
- 108020000411 Toll-like receptor Proteins 0.000 claims description 22
- 102000035181 adaptor proteins Human genes 0.000 claims description 22
- 108091005764 adaptor proteins Proteins 0.000 claims description 22
- 230000003834 intracellular effect Effects 0.000 claims description 22
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 21
- 102000004127 Cytokines Human genes 0.000 claims description 20
- 108090000695 Cytokines Proteins 0.000 claims description 20
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 20
- 239000012636 effector Substances 0.000 claims description 20
- 244000052769 pathogen Species 0.000 claims description 20
- 101710142315 Mitochondrial antiviral-signaling protein Proteins 0.000 claims description 19
- 102100023727 Mitochondrial antiviral-signaling protein Human genes 0.000 claims description 19
- 102000040945 Transcription factor Human genes 0.000 claims description 19
- 108091023040 Transcription factor Proteins 0.000 claims description 19
- 230000036755 cellular response Effects 0.000 claims description 19
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 claims description 18
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 claims description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
- 230000019491 signal transduction Effects 0.000 claims description 18
- 102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 claims description 17
- 206010061218 Inflammation Diseases 0.000 claims description 17
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 claims description 17
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 claims description 17
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 claims description 17
- 210000004443 dendritic cell Anatomy 0.000 claims description 17
- 230000004054 inflammatory process Effects 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 230000015654 memory Effects 0.000 claims description 17
- 101710100501 CASP8 and FADD-like apoptosis regulator Proteins 0.000 claims description 16
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 claims description 16
- 101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 claims description 15
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 claims description 15
- 101100452374 Mus musculus Ikbke gene Proteins 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 claims description 14
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 230000001965 increasing effect Effects 0.000 claims description 14
- 230000028709 inflammatory response Effects 0.000 claims description 14
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 claims description 13
- 102000053956 human IRF7 Human genes 0.000 claims description 13
- 108091008743 testicular receptors 4 Proteins 0.000 claims description 13
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 claims description 12
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 claims description 12
- 108090000426 Caspase-1 Proteins 0.000 claims description 12
- 101710090338 Caspase-4 Proteins 0.000 claims description 12
- 102100025597 Caspase-4 Human genes 0.000 claims description 12
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 claims description 12
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 claims description 12
- 102100023332 Dual specificity mitogen-activated protein kinase kinase 7 Human genes 0.000 claims description 12
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 claims description 12
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 claims description 12
- 101000624594 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 7 Proteins 0.000 claims description 12
- 101001011442 Homo sapiens Interferon regulatory factor 5 Proteins 0.000 claims description 12
- 101001032341 Homo sapiens Interferon regulatory factor 9 Proteins 0.000 claims description 12
- 102100030131 Interferon regulatory factor 5 Human genes 0.000 claims description 12
- 102100038251 Interferon regulatory factor 9 Human genes 0.000 claims description 12
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 claims description 12
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 230000016784 immunoglobulin production Effects 0.000 claims description 12
- 230000010472 type I IFN response Effects 0.000 claims description 12
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 claims description 11
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 claims description 11
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 claims description 11
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 claims description 11
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 claims description 11
- 102100038069 Interferon regulatory factor 8 Human genes 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 101001032345 Homo sapiens Interferon regulatory factor 8 Proteins 0.000 claims description 10
- 101000852255 Homo sapiens Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 claims description 10
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 claims description 10
- 102100036433 Interleukin-1 receptor-associated kinase-like 2 Human genes 0.000 claims description 10
- 230000024932 T cell mediated immunity Effects 0.000 claims description 10
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 claims description 10
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 10
- 101150116749 chuk gene Proteins 0.000 claims description 10
- 238000012217 deletion Methods 0.000 claims description 10
- 230000037430 deletion Effects 0.000 claims description 10
- 230000028996 humoral immune response Effects 0.000 claims description 10
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 10
- 229940045145 uridine Drugs 0.000 claims description 10
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 9
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims description 9
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 claims description 9
- 102100035904 Caspase-1 Human genes 0.000 claims description 9
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims description 9
- 102100039928 Gamma-interferon-inducible protein 16 Human genes 0.000 claims description 9
- 101000960209 Homo sapiens Gamma-interferon-inducible protein 16 Proteins 0.000 claims description 9
- 101710090028 Inositol-3-phosphate synthase 1 Proteins 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 9
- 230000011712 cell development Effects 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- 229940125846 compound 25 Drugs 0.000 claims description 9
- 238000013508 migration Methods 0.000 claims description 9
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 8
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 8
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 8
- 101000674731 Homo sapiens TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 Proteins 0.000 claims description 8
- 101000674728 Homo sapiens TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 Proteins 0.000 claims description 8
- 101000674732 Homo sapiens TGF-beta-activated kinase 1 and MAP3K7-binding protein 3 Proteins 0.000 claims description 8
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims description 8
- 230000006052 T cell proliferation Effects 0.000 claims description 8
- 102100021228 TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 Human genes 0.000 claims description 8
- 102100021227 TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 Human genes 0.000 claims description 8
- 102100021229 TGF-beta-activated kinase 1 and MAP3K7-binding protein 3 Human genes 0.000 claims description 8
- 102100040310 Z-DNA-binding protein 1 Human genes 0.000 claims description 8
- 101710181770 Z-DNA-binding protein 1 Proteins 0.000 claims description 8
- 230000005012 migration Effects 0.000 claims description 8
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 claims description 7
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 7
- 102100038916 Caspase-5 Human genes 0.000 claims description 7
- 101710090333 Caspase-5 Proteins 0.000 claims description 7
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims description 7
- 101000933115 Mus musculus Caspase-4 Proteins 0.000 claims description 7
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 6
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 6
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 6
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims description 6
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 claims description 5
- 101000728679 Homo sapiens Apoptosis-associated speck-like protein containing a CARD Proteins 0.000 claims description 5
- 108010059278 Pyrin Proteins 0.000 claims description 5
- 230000008350 antigen-specific antibody response Effects 0.000 claims description 5
- 238000003776 cleavage reaction Methods 0.000 claims description 5
- 230000007017 scission Effects 0.000 claims description 5
- LRFJOIPOPUJUMI-KWXKLSQISA-N 2-[2,2-bis[(9z,12z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-n,n-dimethylethanamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC1(CCCCCCCC\C=C/C\C=C/CCCCC)OCC(CCN(C)C)O1 LRFJOIPOPUJUMI-KWXKLSQISA-N 0.000 claims description 4
- 229930182558 Sterol Natural products 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 150000003432 sterols Chemical class 0.000 claims description 4
- 235000003702 sterols Nutrition 0.000 claims description 4
- SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 claims description 3
- QCNWZROVPSVEJA-UHFFFAOYSA-N Heptadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCC(O)=O QCNWZROVPSVEJA-UHFFFAOYSA-N 0.000 claims description 3
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 claims description 3
- 230000031146 intracellular signal transduction Effects 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 claims description 2
- VRVXMIJPUBNPGH-XVFCMESISA-N 2-thio-dihydrouridine Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(=O)NC1=S VRVXMIJPUBNPGH-XVFCMESISA-N 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 2
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 2
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 2
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 claims description 2
- 102100038823 RNA-binding protein 45 Human genes 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 101001011663 Homo sapiens Mixed lineage kinase domain-like protein Proteins 0.000 claims 5
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 102100026882 Alpha-synuclein Human genes 0.000 claims 3
- 102100026693 FAS-associated death domain protein Human genes 0.000 claims 3
- 102100037388 Gasdermin-D Human genes 0.000 claims 3
- 101000871228 Homo sapiens Diablo IAP-binding mitochondrial protein Proteins 0.000 claims 3
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 claims 3
- 101001026262 Homo sapiens Gasdermin-D Proteins 0.000 claims 3
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 claims 3
- 102000005583 Pyrin Human genes 0.000 claims 3
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 claims 3
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 claims 3
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- PPUDLEUZKVJXSZ-VPCXQMTMSA-N 4-amino-1-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidin-2-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 PPUDLEUZKVJXSZ-VPCXQMTMSA-N 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000002223 anti-pathogen Effects 0.000 abstract 1
- 206010003402 Arthropod sting Diseases 0.000 description 125
- 208000003014 Bites and Stings Diseases 0.000 description 125
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 78
- 210000004027 cell Anatomy 0.000 description 62
- 241000699670 Mus sp. Species 0.000 description 57
- 241000701806 Human papillomavirus Species 0.000 description 53
- 239000003623 enhancer Substances 0.000 description 49
- 206010057190 Respiratory tract infections Diseases 0.000 description 48
- 125000003275 alpha amino acid group Chemical group 0.000 description 45
- 229960005486 vaccine Drugs 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 34
- 125000003729 nucleotide group Chemical group 0.000 description 34
- 230000001580 bacterial effect Effects 0.000 description 29
- 108700026244 Open Reading Frames Proteins 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 24
- 238000000338 in vitro Methods 0.000 description 21
- 238000010212 intracellular staining Methods 0.000 description 21
- 125000000539 amino acid group Chemical group 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 19
- 238000001994 activation Methods 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 18
- 230000003612 virological effect Effects 0.000 description 18
- 230000004913 activation Effects 0.000 description 17
- 230000003053 immunization Effects 0.000 description 15
- 238000002649 immunization Methods 0.000 description 15
- 210000004989 spleen cell Anatomy 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 14
- 241001529936 Murinae Species 0.000 description 13
- 230000006698 induction Effects 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 239000000969 carrier Substances 0.000 description 11
- 230000036039 immunity Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 10
- 102000001284 I-kappa-B kinase Human genes 0.000 description 10
- 108060006678 I-kappa-B kinase Proteins 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- 101000826387 Homo sapiens Signal transducer and activator of transcription 6 Proteins 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 229960001212 bacterial vaccine Drugs 0.000 description 9
- 239000000306 component Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 102000053955 human IRF3 Human genes 0.000 description 9
- 102000054044 human STAT6 Human genes 0.000 description 9
- 210000004988 splenocyte Anatomy 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 8
- 230000000091 immunopotentiator Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 229960002566 papillomavirus vaccine Drugs 0.000 description 8
- 102100030708 GTPase KRas Human genes 0.000 description 7
- 239000012645 endogenous antigen Substances 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 229940047124 interferons Drugs 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 description 6
- 101710156605 Diablo homolog, mitochondrial Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000009566 cancer vaccine Methods 0.000 description 6
- 229940022399 cancer vaccine Drugs 0.000 description 6
- 230000002519 immonomodulatory effect Effects 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 101000914211 Homo sapiens CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000011275 oncology therapy Methods 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 231100000588 tumorigenic Toxicity 0.000 description 5
- 230000000381 tumorigenic effect Effects 0.000 description 5
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 4
- 108030002637 Cyclic GMP-AMP synthases Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 4
- 101150103227 IFN gene Proteins 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
- 108091027981 Response element Proteins 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 102000044116 human CFLAR Human genes 0.000 description 4
- 230000037449 immunogenic cell death Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 3
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 3
- 102000043138 IRF family Human genes 0.000 description 3
- 108091054729 IRF family Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108090000467 Interferon-beta Proteins 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- 108091007780 MiR-122 Proteins 0.000 description 3
- 101100141312 Mus musculus Ripk1 gene Proteins 0.000 description 3
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 3
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 3
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 3
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 3
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 102000049555 human KRAS Human genes 0.000 description 3
- 230000009851 immunogenic response Effects 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 102200006539 rs121913529 Human genes 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000012646 vaccine adjuvant Substances 0.000 description 3
- 229940124931 vaccine adjuvant Drugs 0.000 description 3
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 3
- 229950008737 vadimezan Drugs 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- KYEKLQMDNZPEFU-KVTDHHQDSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)N=C1 KYEKLQMDNZPEFU-KVTDHHQDSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 102100026548 Caspase-8 Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108700010013 HMGB1 Proteins 0.000 description 2
- 101150021904 HMGB1 gene Proteins 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 102100037907 High mobility group protein B1 Human genes 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 102100021857 Inhibitor of nuclear factor kappa-B kinase subunit epsilon Human genes 0.000 description 2
- 101710164304 Inhibitor of nuclear factor kappa-B kinase subunit epsilon Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241000579048 Merkel cell polyomavirus Species 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 102100039233 Pyrin Human genes 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 2
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 2
- 101710106944 Serine/threonine-protein kinase TBK1 Proteins 0.000 description 2
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 210000003297 immature b lymphocyte Anatomy 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 108700021021 mRNA Vaccine Proteins 0.000 description 2
- 229940126582 mRNA vaccine Drugs 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 2
- 102200006531 rs121913529 Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- VRWARUOVIKCCEQ-WOUKDFQISA-N (2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-methoxy-5-methyloxolan-3-ol Chemical compound C[C@@]1([C@H](OC)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 VRWARUOVIKCCEQ-WOUKDFQISA-N 0.000 description 1
- MUSPKJVFRAYWAR-XVFCMESISA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)S[C@H]1N1C(=O)NC(=O)C=C1 MUSPKJVFRAYWAR-XVFCMESISA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 230000028728 B cell mediated immunity Effects 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 102220577208 B- and T-lymphocyte attenuator_E41K_mutation Human genes 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 230000005724 C-terminal phosphorylation Effects 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 102000004082 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282375 Herpestidae Species 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101100341161 Homo sapiens IRF7 gene Proteins 0.000 description 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
- 101001043761 Homo sapiens Inhibitor of nuclear factor kappa-B kinase subunit epsilon Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000978490 Homo sapiens Mitochondrial antiviral-signaling protein Proteins 0.000 description 1
- 101000981728 Homo sapiens Myeloid differentiation primary response protein MyD88 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 1
- 101710199010 Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 108010043610 KIR Receptors Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 101001043758 Mus musculus Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 1
- 101100238610 Mus musculus Msh3 gene Proteins 0.000 description 1
- 101100079026 Mus musculus Myd88 gene Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100297655 Rattus norvegicus Pim3 gene Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- UZHDGDDPOPDJGM-UHFFFAOYSA-N Stigmatellin A Natural products COC1=CC(OC)=C2C(=O)C(C)=C(CCC(C)C(OC)C(C)C(C=CC=CC(C)=CC)OC)OC2=C1O UZHDGDDPOPDJGM-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 108091021474 TMEM173 Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- JSBNEYNPYQFYNM-UHFFFAOYSA-J YoYo-3 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=CC=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC(=[N+](C)C)CCCC(=[N+](C)C)CC[N+](C1=CC=CC=C11)=CC=C1C=CC=C1N(C)C2=CC=CC=C2O1 JSBNEYNPYQFYNM-UHFFFAOYSA-J 0.000 description 1
- 101150086963 Znf354a gene Proteins 0.000 description 1
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000008267 autocrine signaling Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000053347 human IKBKE Human genes 0.000 description 1
- 102000054014 human IRF1 Human genes 0.000 description 1
- 102000056488 human MAVS Human genes 0.000 description 1
- 102000051360 human TBK1 Human genes 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000854 inhibitional effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 108010051621 interferon regulatory factor-8 Proteins 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 230000011542 interferon-beta production Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 108700041430 link Proteins 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 108091051828 miR-122 stem-loop Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000016412 positive regulation of cytokine production Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 102200006532 rs112445441 Human genes 0.000 description 1
- 102200006538 rs121913530 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662412933P | 2016-10-26 | 2016-10-26 | |
| US62/412,933 | 2016-10-26 | ||
| US201762467034P | 2017-03-03 | 2017-03-03 | |
| US62/467,034 | 2017-03-03 | ||
| US201762490522P | 2017-04-26 | 2017-04-26 | |
| US62/490,522 | 2017-04-26 | ||
| US201762558206P | 2017-09-13 | 2017-09-13 | |
| US62/558,206 | 2017-09-13 | ||
| PCT/US2017/058585 WO2018081459A1 (en) | 2016-10-26 | 2017-10-26 | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190086681A true KR20190086681A (ko) | 2019-07-23 |
Family
ID=60570181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197014935A Withdrawn KR20190086681A (ko) | 2016-10-26 | 2017-10-26 | 면역 반응을 향상시키기 위한 메신저 리보핵산 및 그의 사용 방법 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20180311343A1 (enExample) |
| EP (1) | EP3532070A1 (enExample) |
| JP (2) | JP2019532657A (enExample) |
| KR (1) | KR20190086681A (enExample) |
| CN (1) | CN110402145A (enExample) |
| AU (1) | AU2017347837A1 (enExample) |
| BR (1) | BR112019008369A2 (enExample) |
| CA (1) | CA3042015A1 (enExample) |
| IL (1) | IL266222A (enExample) |
| MX (1) | MX2019004810A (enExample) |
| RU (1) | RU2765874C2 (enExample) |
| SG (1) | SG11201903674YA (enExample) |
| WO (1) | WO2018081459A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200109325A (ko) * | 2018-01-18 | 2020-09-22 | 프레드 헛친슨 켄서 리서치 센터 | 세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경 |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4349405A3 (en) | 2015-10-22 | 2024-06-19 | ModernaTX, Inc. | Respiratory virus vaccines |
| EA201891001A1 (ru) | 2015-10-22 | 2018-11-30 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv) |
| EP3364982A4 (en) | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES |
| ES2924407T3 (es) | 2015-12-10 | 2022-10-06 | Modernatx Inc | Composiciones y procedimientos para el suministro de agentes terapéuticos |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| EP3458107B1 (en) | 2016-05-18 | 2024-03-13 | ModernaTX, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| AU2017268394A1 (en) | 2016-05-18 | 2019-01-03 | Modernatx, Inc. | Polynucleotides encoding relaxin |
| CN109937253B (zh) | 2016-09-14 | 2023-06-30 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
| MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| EP3538146A4 (en) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | INFLUENZA VACCINE |
| MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| JP2020515522A (ja) * | 2017-01-27 | 2020-05-28 | ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | 免疫応答を誘導するヘルペスウイルスエンベロープタンパク質の組み合わせのワクチン組成物 |
| CN110505877A (zh) * | 2017-02-01 | 2019-11-26 | 摩登纳特斯有限公司 | Rna癌症疫苗 |
| US20190351039A1 (en) | 2017-02-01 | 2019-11-21 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Respiratory syncytial virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| EP3595676A4 (en) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
| EP3607074A4 (en) | 2017-04-05 | 2021-07-07 | Modernatx, Inc. | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY |
| EP3625345B1 (en) | 2017-05-18 | 2023-05-24 | ModernaTX, Inc. | Modified messenger rna comprising functional rna elements |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| US11168326B2 (en) | 2017-07-11 | 2021-11-09 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| WO2019035901A1 (en) * | 2017-08-15 | 2019-02-21 | University Of Miami | COMPOSITIONS AND METHODS FOR STING PROTEIN MODULATION |
| EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | HPLC ANALYTICAL PROCESSES |
| EP3668979A4 (en) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | METHOD OF HPLC ANALYSIS |
| EP4397757A3 (en) | 2017-08-18 | 2024-10-23 | ModernaTX, Inc. | Rna polymerase variants |
| US11744801B2 (en) | 2017-08-31 | 2023-09-05 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| GB201714430D0 (en) | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
| WO2019121803A1 (en) | 2017-12-21 | 2019-06-27 | Baseclick Gmbh | Click-modified mrna |
| MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
| EP3746052A1 (en) * | 2018-01-30 | 2020-12-09 | Modernatx, Inc. | Compositions and methods for delivery of agents to immune cells |
| CA3097850A1 (en) * | 2018-03-26 | 2019-10-03 | University Of Miami | Recombinant viral vector and uses thereof |
| US20210163928A1 (en) * | 2018-04-11 | 2021-06-03 | Modernatx, Inc. | Messenger rna comprising functional rna elements |
| SG11202011587PA (en) * | 2018-05-30 | 2020-12-30 | Translate Bio Inc | Messenger rna vaccines and uses thereof |
| US11981909B2 (en) | 2018-06-06 | 2024-05-14 | Massachusetts Institute Of Technology | Circular RNA for translation in eukaryotic cells |
| JP7340591B2 (ja) | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
| WO2020028743A1 (en) * | 2018-08-03 | 2020-02-06 | Board Of Trustees Of Michigan State University | Compositions of sting variants, combinations thereof, and methods for inducing and enhancing an immune response against infections, diseases, and disorders |
| US20220002730A1 (en) * | 2018-08-24 | 2022-01-06 | City Of Hope | Oligonucleotide inhibitors of nuclear factor kappa-light-chain-enhancer of activated b cells and the uses thereof |
| EP3844276A2 (en) | 2018-08-28 | 2021-07-07 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| WO2020061284A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| JP7640452B2 (ja) | 2018-09-19 | 2025-03-05 | モデルナティエックス インコーポレイテッド | 高純度ｐｅｇ脂質及びそれらの使用 |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US20210330600A1 (en) * | 2018-12-21 | 2021-10-28 | Tiba Biotech Llc | Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same |
| CN109762895A (zh) * | 2019-01-07 | 2019-05-17 | 中国医学科学院北京协和医院 | miR-146a在制备诊断激素性股骨头坏死产品中的应用 |
| EP3683229A1 (en) * | 2019-01-21 | 2020-07-22 | Charité - Universitätsmedizin Berlin | Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| MA55037A (fr) | 2019-02-20 | 2021-12-29 | Modernatx Inc | Variants d'arn polymérase pour le coiffage co-transcriptionnel |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| CA3176660A1 (en) | 2019-02-27 | 2020-09-03 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| MX2021011031A (es) | 2019-03-11 | 2021-12-10 | Modernatx Inc | Proceso de transcripción in vitro en lotes alimentados. |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| EP3946434A1 (en) | 2019-04-02 | 2022-02-09 | Immunetune B.V. | Immune-stimulatory compositions and use thereof |
| CN115867291A (zh) | 2019-05-22 | 2023-03-28 | 麻省理工学院 | 环状rna组合物和方法 |
| AU2020299636A1 (en) * | 2019-07-03 | 2022-02-24 | The Walter And Eliza Hall Institute Of Medical Research | Compositions and methods of use |
| US11666624B2 (en) | 2019-09-24 | 2023-06-06 | Auburn University | Phage-peptide constructs for stimulating an immune response against CD47 |
| EP4529928A3 (en) * | 2019-10-09 | 2025-05-28 | Translate Bio, Inc. | Compositions, methods and uses of messenger rna |
| WO2021081296A1 (en) * | 2019-10-24 | 2021-04-29 | Joshua Labaer | Novel antibodies for detecting epstein barr virus-positive gastric cancer |
| IL292836A (en) | 2019-11-12 | 2022-07-01 | Actym Therapeutics Inc | Platforms for administering bacteria that stimulate the immune system and their use for administering therapeutic products |
| JP7668549B2 (ja) * | 2019-11-14 | 2025-04-25 | ボアズィチ ウニヴェルシテシ | がん免疫療法におけるａｓｃスペック |
| WO2021095838A1 (ja) * | 2019-11-15 | 2021-05-20 | 第一三共株式会社 | ＨＰＶ ｍＲＮＡを封入した核酸脂質粒子ワクチン |
| US20210154281A1 (en) * | 2019-11-26 | 2021-05-27 | Massachusetts Institute Of Technology | Cell-based cancer vaccines and cancer therapies |
| MX2022006854A (es) | 2019-12-04 | 2022-11-30 | Orna Therapeutics Inc | Composiciones y metodos de arn circular. |
| AU2020405068A1 (en) | 2019-12-18 | 2022-07-07 | Stinginn Llc | Substituted 1,2, 4-triazoles and methods of use |
| CN110974954B (zh) * | 2019-12-24 | 2021-03-16 | 珠海丽凡达生物技术有限公司 | 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法 |
| WO2021168266A1 (en) * | 2020-02-21 | 2021-08-26 | Temple University - Of The Commonwealth System Of Higher Education | Eradication of merkel cell polyomavirus |
| IL295724A (en) * | 2020-02-21 | 2022-10-01 | Combined Therapeutics Inc | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
| WO2021197589A1 (en) * | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
| KR20230005241A (ko) | 2020-04-22 | 2023-01-09 | 넛크래커 테라퓨틱스 인코포레이티드 | mRNA 치료 나노입자 |
| WO2021213924A1 (en) | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
| US11897888B1 (en) | 2020-04-30 | 2024-02-13 | Stinginn Llc | Small molecular inhibitors of sting signaling compositions and methods of use |
| KR20230035576A (ko) * | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| CA3187345A1 (en) * | 2020-07-31 | 2022-02-17 | Romain MICOL | Compositions and methods for improved vaccination |
| WO2022032196A2 (en) * | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
| AU2021324883A1 (en) | 2020-08-12 | 2023-03-23 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US20240026317A1 (en) * | 2020-10-14 | 2024-01-25 | Dong Shen | PAN-RAS mRNA CANCER VACCINES |
| GB202017119D0 (en) * | 2020-10-28 | 2020-12-09 | Oxford Vacmedix Uk Ltd | Polypeptides for cancer treatment |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| WO2022109220A1 (en) * | 2020-11-20 | 2022-05-27 | Think Therapeutics, Inc. | Compositions and methods for optimized peptide vaccines |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| GB202020063D0 (en) * | 2020-12-17 | 2021-02-03 | Imperial College Innovations Ltd | RNA construct |
| WO2022140588A1 (en) * | 2020-12-23 | 2022-06-30 | Kernal Biologics, Inc. | Constitutively active payloads |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| WO2022155421A1 (en) * | 2021-01-15 | 2022-07-21 | University Of Rochester | Staphylococcus aureus antigen-based nucleic acid vaccines |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| KR20230165276A (ko) * | 2021-03-31 | 2023-12-05 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도 |
| CN113509542A (zh) * | 2021-04-20 | 2021-10-19 | 嘉晨西海(杭州)生物技术有限公司 | 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法 |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| EP4342993A4 (en) * | 2021-05-19 | 2025-05-28 | Daiichi Sankyo Company, Limited | Hpv infectious disease vaccine |
| WO2022256637A2 (en) * | 2021-06-03 | 2022-12-08 | David Weiner | Synthetic dna vaccine immunogenic improvements |
| CA3224943A1 (en) * | 2021-07-06 | 2023-01-12 | Erin Kathleen Reagan | P7 containing nucleoside-modified mrna-lipid nanoparticle lineage vaccine for hepatitis c virus |
| CN113616793B (zh) * | 2021-08-20 | 2023-07-04 | 南方海洋科学与工程广东省实验室(湛江) | Traf6抑制剂在作为和/或制备铁死亡诱导剂中的应用 |
| WO2023076131A2 (en) * | 2021-10-25 | 2023-05-04 | The Regents Of The University Of California | Kaposi sarcoma associated herpesvirus gene function |
| EP4429682A2 (en) | 2021-11-09 | 2024-09-18 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| CN113952359A (zh) * | 2021-11-19 | 2022-01-21 | 大连理工大学盘锦产业技术研究院 | 顺铂与Tri-1的联合抗肺癌药物组合物及其应用 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| CN116376942A (zh) * | 2021-12-31 | 2023-07-04 | 广州国家实验室 | mRNA疫苗 |
| CA3248846A1 (en) * | 2022-01-17 | 2023-07-20 | Sanofi | Lipid Compounds and Their Uses |
| TW202345864A (zh) * | 2022-02-18 | 2023-12-01 | 美商現代公司 | 編碼檢查點癌症疫苗之ｍＲＮＡ及其用途 |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| CN115089588A (zh) * | 2022-08-22 | 2022-09-23 | 云南大学 | 达沙布韦作为e3连接酶新型配体构建protac的应用 |
| WO2025087250A1 (en) * | 2023-10-23 | 2025-05-01 | Abogen Biosciences (Shanghai) Co., Ltd. | Therapeutic mrna cancer vaccine targeting hpv-associated cancers |
| WO2025087266A1 (en) * | 2023-10-23 | 2025-05-01 | Abogen Biosciences (Shanghai) Co., Ltd. | Immunomodulatory mrna cassettes, and uses thereof |
| CN119662655A (zh) * | 2023-12-04 | 2025-03-21 | 武汉厚先生物医药有限公司 | Rna分子及其组合物在肿瘤免疫治疗中的应用 |
| WO2025153053A1 (en) * | 2024-01-17 | 2025-07-24 | Abogen Biosciences (Shanghai) Co., Ltd. | Composition and methods for inducing antigen specific immunity against kras mutant cells |
| CN118839285B (zh) * | 2024-08-05 | 2025-03-18 | 洛阳莱普生信息科技有限公司 | 基于智能耳标的畜牧生物资产监管方法及系统 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| AU3559695A (en) | 1994-09-30 | 1996-04-26 | Inex Pharmaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
| IL161100A0 (en) | 2001-09-28 | 2004-08-31 | Max Planck Gesellschaft | Identification of novel genes coding for small temporal rnas |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| EP1648914A4 (en) | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| DE102004035227A1 (de) * | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| CN101384273B (zh) | 2006-01-05 | 2013-07-10 | 俄亥俄州立大学研究基金会 | 胰腺内分泌和腺泡肿瘤中的微小rna表达异常 |
| CN103642900B (zh) | 2006-01-05 | 2016-04-13 | 俄亥俄州立大学研究基金会 | 用于诊断和治疗实体癌的基于微小rna的方法和组合物 |
| CA2638844C (en) | 2006-03-02 | 2016-05-03 | Thomas D. Schmittgen | Microrna expression profile associated with pancreatic cancer |
| WO2008036765A2 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| EP2087135B8 (en) | 2006-11-01 | 2013-07-24 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
| CN101622349A (zh) | 2006-12-08 | 2010-01-06 | 奥斯瑞根公司 | 作为治疗性干预靶标的miR-21调节的基因和途径 |
| WO2008147974A1 (en) | 2007-05-23 | 2008-12-04 | University Of South Florida | Micro-rnas modulating immunity and inflammation |
| WO2008154098A2 (en) | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
| ES2573458T3 (es) * | 2007-09-14 | 2016-06-08 | Vrije Universiteit Brussel | Mejoramiento de la capacidad estimulatoria de las células T de las células que presentan antígeno humano y su uso en vacunación |
| AU2008329755A1 (en) | 2007-11-30 | 2009-06-04 | The Ohio State University Research Foundation | MicroRNA expression profiling and targeting in peripheral blood in lung cancer |
| US20090263803A1 (en) | 2008-02-08 | 2009-10-22 | Sylvie Beaudenon | Mirnas differentially expressed in lymph nodes from cancer patients |
| US20110052502A1 (en) | 2008-02-28 | 2011-03-03 | The Ohio State University Research Foundation | MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CCL) and Uses Thereof |
| EP2112235A1 (en) | 2008-04-24 | 2009-10-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma |
| WO2009149539A1 (en) * | 2008-06-10 | 2009-12-17 | Université de Montréal | Enhancing antigen-specific cd8+ t cell response using irf-7 mrna |
| WO2010018563A2 (en) | 2008-08-12 | 2010-02-18 | Rosetta Genomics Ltd. | Compositions and methods for the prognosis of lymphoma |
| WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| WO2010055487A2 (en) | 2008-11-13 | 2010-05-20 | Koninklijke Philips Electronics N.V. | Compositions and methods for micro-rna expession profiling of colorectal cancer |
| WO2010066384A1 (en) | 2008-12-10 | 2010-06-17 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Compositions and methods for micro-rna expression profiling of cancer stem cells |
| WO2010129860A2 (en) | 2009-05-08 | 2010-11-11 | The Ohio State University Research Foundation | Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof |
| KR102066189B1 (ko) | 2009-06-10 | 2020-01-14 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| WO2011076143A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expression profiling of lung cancer |
| WO2011076142A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
| EP2341145A1 (en) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
| WO2011094683A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
| EP2354246A1 (en) | 2010-02-05 | 2011-08-10 | febit holding GmbH | miRNA in the diagnosis of ovarian cancer |
| WO2011113030A2 (en) | 2010-03-11 | 2011-09-15 | H.Lee Moffitt Cancer Center & Research Institute | Human cancer micro-rna expression profiles predictive of chemo-response |
| WO2011157294A1 (en) | 2010-06-16 | 2011-12-22 | Universita' Degli Studi Di Padova | Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto |
| CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| SI2633034T1 (en) * | 2010-10-26 | 2018-05-31 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Dendritic cells with manipulated signal path NFkB |
| US9999673B2 (en) | 2011-01-11 | 2018-06-19 | Alnylam Pharmaceuticals, Inc. | PEGylated lipids and their use for drug delivery |
| WO2012136653A1 (en) | 2011-04-08 | 2012-10-11 | Novvac Aps | Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus |
| US20140113978A1 (en) | 2011-05-01 | 2014-04-24 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
| EP2944961A1 (en) | 2011-05-06 | 2015-11-18 | XenTech | Markers for cancer prognosis and therapy and methods of use |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| ES2987057T3 (es) | 2011-06-08 | 2024-11-13 | Translate Bio Inc | Lípidos escindibles |
| ES2610245T3 (es) | 2011-07-15 | 2017-04-26 | Leo Pharma A/S | Perfilado de microARN para el diagnóstico en linfoma cutáneo de células T (CTCL) |
| US20150080243A1 (en) | 2011-09-01 | 2015-03-19 | Allegro Diagnostics Corp. | Methods and compositions for detecting cancer based on mirna expression profiles |
| WO2013066678A1 (en) | 2011-10-26 | 2013-05-10 | Georgetown University | Microrna expression profiling of thyroid cancer |
| HK1200089A1 (en) | 2011-12-07 | 2015-07-31 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| WO2013116126A1 (en) | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| ES2642892T3 (es) | 2012-03-05 | 2017-11-20 | University Of Maryland, Baltimore | Protección de vacuna multivalente contra la infección por estafilococo aureus |
| AU2013243952A1 (en) * | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2014039961A1 (en) * | 2012-09-07 | 2014-03-13 | University Of Miami | Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| SMT202200337T1 (it) | 2012-11-26 | 2022-09-14 | Modernatx Inc | Rna modificato al livello del terminale |
| AU2013374345A1 (en) | 2013-01-17 | 2015-08-06 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| HK1220122A1 (zh) | 2013-03-09 | 2017-04-28 | Modernatx, Inc. | Mrna的异源未转录区域 |
| EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US20160368952A1 (en) | 2013-12-03 | 2016-12-22 | Evaxion Biotech Aps | Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus |
| WO2015130584A2 (en) | 2014-02-25 | 2015-09-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| SG10201912038TA (en) * | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| DK3140320T3 (en) | 2014-05-06 | 2019-04-15 | Targovax Asa | PEPTID VACCINE CONTAINING MUTANT RACE PEPTID AND CHEMOTHERAPEUTIC AGENTS |
| IL298516B2 (en) | 2014-06-25 | 2025-03-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle compositions for nucleic acid delivery |
| JP6912384B2 (ja) * | 2015-04-22 | 2021-08-04 | キュアバック アーゲー | 癌疾患の処置のための、ｒｎａ含有組成物 |
| US20180303925A1 (en) * | 2015-04-27 | 2018-10-25 | The Trustees Of The University Of Pennsylvania | Nucleoside-Modified RNA For Inducing an Adaptive Immune Response |
| WO2017020026A1 (en) * | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| RS63986B1 (sr) | 2015-10-28 | 2023-03-31 | Acuitas Therapeutics Inc | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
-
2017
- 2017-10-26 CN CN201780080846.2A patent/CN110402145A/zh active Pending
- 2017-10-26 KR KR1020197014935A patent/KR20190086681A/ko not_active Withdrawn
- 2017-10-26 RU RU2019116006A patent/RU2765874C2/ru active
- 2017-10-26 AU AU2017347837A patent/AU2017347837A1/en not_active Abandoned
- 2017-10-26 BR BR112019008369A patent/BR112019008369A2/pt not_active Application Discontinuation
- 2017-10-26 WO PCT/US2017/058585 patent/WO2018081459A1/en not_active Ceased
- 2017-10-26 SG SG11201903674YA patent/SG11201903674YA/en unknown
- 2017-10-26 JP JP2019522512A patent/JP2019532657A/ja active Pending
- 2017-10-26 MX MX2019004810A patent/MX2019004810A/es unknown
- 2017-10-26 CA CA3042015A patent/CA3042015A1/en active Pending
- 2017-10-26 EP EP17808634.4A patent/EP3532070A1/en not_active Withdrawn
-
2018
- 2018-06-01 US US15/995,519 patent/US20180311343A1/en not_active Abandoned
-
2019
- 2019-04-24 IL IL266222A patent/IL266222A/en unknown
- 2019-11-01 US US16/671,921 patent/US20200261572A1/en not_active Abandoned
-
2022
- 2022-09-09 JP JP2022143786A patent/JP2022184924A/ja active Pending
-
2024
- 2024-06-27 US US18/756,934 patent/US20250170235A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200109325A (ko) * | 2018-01-18 | 2020-09-22 | 프레드 헛친슨 켄서 리서치 센터 | 세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250170235A1 (en) | 2025-05-29 |
| MX2019004810A (es) | 2019-10-15 |
| RU2765874C2 (ru) | 2022-02-04 |
| SG11201903674YA (en) | 2019-05-30 |
| JP2022184924A (ja) | 2022-12-13 |
| RU2019116006A (ru) | 2020-11-27 |
| BR112019008369A2 (pt) | 2019-10-01 |
| US20200261572A1 (en) | 2020-08-20 |
| CA3042015A1 (en) | 2018-05-03 |
| JP2019532657A (ja) | 2019-11-14 |
| WO2018081459A1 (en) | 2018-05-03 |
| AU2017347837A1 (en) | 2019-06-06 |
| WO2018081459A9 (en) | 2018-11-22 |
| CN110402145A (zh) | 2019-11-01 |
| IL266222A (en) | 2019-06-30 |
| RU2019116006A3 (enExample) | 2021-07-30 |
| EP3532070A1 (en) | 2019-09-04 |
| US20180311343A1 (en) | 2018-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20190086681A (ko) | 면역 반응을 향상시키기 위한 메신저 리보핵산 및 그의 사용 방법 | |
| US10881730B2 (en) | Immunomodulatory therapeutic MRNA compositions encoding activating oncogene mutation peptides | |
| RU2768829C2 (ru) | Противораковые рнк-вакцины | |
| WO2023107999A2 (en) | Herpes simplex virus mrna vaccines | |
| JP2018524335A (ja) | Ｈｉｖ予備免疫化および免疫療法 | |
| EP4658306A1 (en) | Epstein-barr virus mrna vaccines | |
| US20250319177A1 (en) | Rna compositions for delivery of monkeypox antigens and related methods | |
| WO2021095838A1 (ja) | ＨＰＶ ｍＲＮＡを封入した核酸脂質粒子ワクチン | |
| WO2024026482A1 (en) | Lipid nanoparticle compositions comprising surface lipid derivatives and related uses | |
| IT202000009688A1 (it) | Proteine di fusione di ancoraggio a esosomi | |
| CN118240844A (zh) | 带状疱疹mRNA疫苗及其制备方法和应用 | |
| Li et al. | Prevention and treatment of HPV‐related cancer through a mRNA vaccine expressing APC‐targeting antigen | |
| US20210355168A1 (en) | Chimeric antigen with enhanced multi-immune function through specific binding to target cell, and use thereof | |
| CN118946365A (zh) | 编码检查点癌症疫苗的mRNA及其用途 | |
| JP2025507571A (ja) | チェックポイントがんワクチンをコードするｍＲＮＡ及びその使用 | |
| JP2025535760A (ja) | ｍＲＮＡ治療用組成物 | |
| JP2023546202A (ja) | Ｈｅｋ２９３細胞株を製造するための方法、ｅｂ－ｖｌｐを製造するための方法、およびｅｂ－ｖｌｐを含む組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190524 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20201022 Comment text: Request for Examination of Application |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20220615 |
|
| WITB | Written withdrawal of application |